Skip to content
Research/Peptides/FOXO4-DRI

FOXO4-DRI

D-Retro-Inverso-retro-inverso peptide. Blocks FOXO4-p53 interaction, induces apoptosis in senescent cells. Senolytic, clearance of "zombie cells".

Intelligence Profile

Science

Mechanism of Action

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic peptide designed to selectively eliminate senescent cells by disrupting a key protein-protein interaction that keeps these aged cells alive. The compound works through a targeted molecular mechanism involving the FOXO4-p53 signaling axis.

Core Molecular Target

The primary target of FOXO4-DRI is the interaction between FOXO4 (Forkhead Box O4) transcription factor and the p53 tumor suppressor protein. Research has identified that "the disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI" (Nature Communications, 2025). This interaction is crucial for senescent cell survival, as FOXO4 normally sequesters p53 in the nucleus of senescent cells, preventing p53 from triggering apoptosis.

Disruption of Protective Signaling

FOXO4-DRI functions by competitively binding to p53, thereby displacing FOXO4 from this interaction. Studies demonstrate that "FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway" (Frontiers in Bioengineering and Biotechnology, 2025). When FOXO4-DRI disrupts the FOXO4-p53 complex, it leads to several downstream effects:

  1. Nuclear exclusion of p53: Research shows that "FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation" (Communications Biology, 2025).

  2. Restoration of p53 pro-apoptotic function: Once freed from FOXO4 sequestration, p53 can resume its normal tumor suppressor activities, including the induction of apoptosis in damaged senescent cells.

Selective Senescent Cell Elimination

The mechanism appears to be selective for senescent cells because these cells have accumulated sufficient cellular damage and stress signals that, when p53 function is restored, they are preferentially eliminated through apoptosis. Normal, healthy cells with intact cellular repair mechanisms are less affected by this intervention.

Therapeutic Applications

Evidence suggests this mechanism has been tested across multiple tissue types and conditions. Studies have shown effects in:

  • Endothelial cells and vascular aging
  • Fibroblasts in pulmonary fibrosis models, where "FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice" (Naunyn-Schmiedeberg's Archives of Pharmacology, 2023)
  • Reproductive aging, where "FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells" (Experimental Gerontology, 2024)

The evidence base is primarily from preclinical studies, and the long-term effects and optimal dosing strategies in humans remain to be established. The mechanism represents a novel approach to targeting cellular senescence, though more research is needed to fully understand its therapeutic potential and safety profile in clinical applications.